208 related articles for article (PubMed ID: 17299604)
1. CXCR2--the receptor to hit?
Reutershan J
Drug News Perspect; 2006 Dec; 19(10):615-23. PubMed ID: 17299604
[TBL] [Abstract][Full Text] [Related]
2. CXCR2 blockade impairs angiotensin II-induced CC chemokine synthesis and mononuclear leukocyte infiltration.
Abu Nabah YN; Losada M; Estellés R; Mateo T; Company C; Piqueras L; Lopez-Gines C; Sarau H; Cortijo J; Morcillo EJ; Jose PJ; Sanz MJ
Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2370-6. PubMed ID: 17717298
[TBL] [Abstract][Full Text] [Related]
3. CXCR2 antagonists for the treatment of pulmonary disease.
Chapman RW; Phillips JE; Hipkin RW; Curran AK; Lundell D; Fine JS
Pharmacol Ther; 2009 Jan; 121(1):55-68. PubMed ID: 19026683
[TBL] [Abstract][Full Text] [Related]
4. ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets.
Bizzarri C; Beccari AR; Bertini R; Cavicchia MR; Giorgini S; Allegretti M
Pharmacol Ther; 2006 Oct; 112(1):139-49. PubMed ID: 16720046
[TBL] [Abstract][Full Text] [Related]
5. Structural determinants of MIF functions in CXCR2-mediated inflammatory and atherogenic leukocyte recruitment.
Weber C; Kraemer S; Drechsler M; Lue H; Koenen RR; Kapurniotu A; Zernecke A; Bernhagen J
Proc Natl Acad Sci U S A; 2008 Oct; 105(42):16278-83. PubMed ID: 18852457
[TBL] [Abstract][Full Text] [Related]
6. CXCR2 inhibition suppresses hemorrhage-induced priming for acute lung injury in mice.
Lomas-Neira JL; Chung CS; Grutkoski PS; Miller EJ; Ayala A
J Leukoc Biol; 2004 Jul; 76(1):58-64. PubMed ID: 15123771
[TBL] [Abstract][Full Text] [Related]
7. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment.
Bernhagen J; Krohn R; Lue H; Gregory JL; Zernecke A; Koenen RR; Dewor M; Georgiev I; Schober A; Leng L; Kooistra T; Fingerle-Rowson G; Ghezzi P; Kleemann R; McColl SR; Bucala R; Hickey MJ; Weber C
Nat Med; 2007 May; 13(5):587-96. PubMed ID: 17435771
[TBL] [Abstract][Full Text] [Related]
8. Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2.
Traves SL; Smith SJ; Barnes PJ; Donnelly LE
J Leukoc Biol; 2004 Aug; 76(2):441-50. PubMed ID: 15155777
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor.
Widdowson KL; Elliott JD; Veber DF; Nie H; Rutledge MC; McCleland BW; Xiang JN; Jurewicz AJ; Hertzberg RP; Foley JJ; Griswold DE; Martin L; Lee JM; White JR; Sarau HM
J Med Chem; 2004 Mar; 47(6):1319-21. PubMed ID: 14998320
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and evaluation of novel 3-amino-4-hydrazine-cyclobut-3-ene-1,2-diones as potent and selective CXCR2 chemokine receptor antagonists.
Liu S; Liu Y; Wang H; Ding Y; Wu H; Dong J; Wong A; Chen SH; Li G; Chan M; Sawyer N; Gervais FG; Henault M; Kargman S; Bedard LL; Han Y; Friesen R; Lobell RB; Stout DM
Bioorg Med Chem Lett; 2009 Oct; 19(19):5741-5. PubMed ID: 19713110
[TBL] [Abstract][Full Text] [Related]
11. Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non-competitive allosteric inhibitor.
Bertini R; Barcelos LS; Beccari AR; Cavalieri B; Moriconi A; Bizzarri C; Di Benedetto P; Di Giacinto C; Gloaguen I; Galliera E; Corsi MM; Russo RC; Andrade SP; Cesta MC; Nano G; Aramini A; Cutrin JC; Locati M; Allegretti M; Teixeira MM
Br J Pharmacol; 2012 Jan; 165(2):436-54. PubMed ID: 21718305
[TBL] [Abstract][Full Text] [Related]
12. High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras.
Wislez M; Fujimoto N; Izzo JG; Hanna AE; Cody DD; Langley RR; Tang H; Burdick MD; Sato M; Minna JD; Mao L; Wistuba I; Strieter RM; Kurie JM
Cancer Res; 2006 Apr; 66(8):4198-207. PubMed ID: 16618742
[TBL] [Abstract][Full Text] [Related]
13. Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2.
Moriconi A; Cesta MC; Cervellera MN; Aramini A; Coniglio S; Colagioia S; Beccari AR; Bizzarri C; Cavicchia MR; Locati M; Galliera E; Di Benedetto P; Vigilante P; Bertini R; Allegretti M
J Med Chem; 2007 Aug; 50(17):3984-4002. PubMed ID: 17665889
[TBL] [Abstract][Full Text] [Related]
14. Reversing systemic inflammatory response syndrome with chemokine receptor pepducins.
Kaneider NC; Agarwal A; Leger AJ; Kuliopulos A
Nat Med; 2005 Jun; 11(6):661-5. PubMed ID: 15880119
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist.
Gonsiorek W; Fan X; Hesk D; Fossetta J; Qiu H; Jakway J; Billah M; Dwyer M; Chao J; Deno G; Taveras A; Lundell DJ; Hipkin RW
J Pharmacol Exp Ther; 2007 Aug; 322(2):477-85. PubMed ID: 17496166
[TBL] [Abstract][Full Text] [Related]
16. Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease.
Donnelly LE; Barnes PJ
Trends Pharmacol Sci; 2006 Oct; 27(10):546-53. PubMed ID: 16911834
[TBL] [Abstract][Full Text] [Related]
17. An apparent paradox: chemokine receptor agonists can be used for anti-inflammatory therapy.
Ali S; O'Boyle G; Mellor P; Kirby JA
Mol Immunol; 2007 Mar; 44(7):1477-82. PubMed ID: 17000001
[TBL] [Abstract][Full Text] [Related]
18. Blockade of CXCR2 signalling: a potential therapeutic target for preventing neutrophil-mediated inflammatory diseases.
Boppana NB; Devarajan A; Gopal K; Barathan M; Bakar SA; Shankar EM; Ebrahim AS; Farooq SM
Exp Biol Med (Maywood); 2014 May; 239(5):509-18. PubMed ID: 24625439
[TBL] [Abstract][Full Text] [Related]
19. Prospective study of neutrophil chemokine responses in trauma patients at risk for pneumonia.
Tarlowe MH; Duffy A; Kannan KB; Itagaki K; Lavery RF; Livingston DH; Bankey P; Hauser CJ
Am J Respir Crit Care Med; 2005 Apr; 171(7):753-9. PubMed ID: 15618463
[TBL] [Abstract][Full Text] [Related]
20. CXCR2 in acute lung injury.
Konrad FM; Reutershan J
Mediators Inflamm; 2012; 2012():740987. PubMed ID: 22719179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
